Gilead Seals VLs For Lenacapavir Amid Concerns Around Price, API Supplies

Gilead strikes voluntary licensing agreements with six generic manufacturers for lenacapavir but health groups seek clarity on pricing and seeming API supply restrictions. All eyes are also on the patent opposition case in India.

Gilead
Gilead seals licensing deals for breakthrough HIV therapy

More from Deals

More from Business